#GLP-1

CMS ha retrasado indefinidamente un programa piloto de Medicare centrado en la cobertura de medicamentos para la obesidad después de que los planes de seguros indicaran que no estaban listos para participar.

Novo Nordisk está gestionando dos salidas al mismo tiempo, incluida la jubilación de la pionera de GLP-1 Lotte Bjerre Knudsen y la marcha de una líder de obesidad a Boehringer Ingelheim.

Un estudio anunciado por el 23andMe Research Institute identificó predictores genéticos vinculados tanto a la eficacia de los GLP-1 para bajar de peso como a sus efectos secundarios, lo que apunta a una posible vía hacia un tratamiento de la obesidad más personalizado.

Two phase 3 EVOKE(+) trials found that semaglutide did not slow clinical progression in Alzheimer’s disease, despite earlier signals that GLP-1 drugs might help.

Structure Therapeutics reporta resultados alentadores de Fase 2 para su agonista del receptor GLP-1 oral, avanzando una alternativa en forma de píldora a los medicamentos inyectables para pérdida de peso y diabetes.

After years of development challenges, oral GLP-1 weight loss drugs are finally hitting the market. Novo Nordisk's oral Wegovy is already available, with Eli Lilly's orforglipron expected to win FDA approval soon.

Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.

Eli Lilly launches a program to make it easier for employers to add GLP-1 weight loss and diabetes drugs to their health plans, addressing a major coverage gap.

Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.

With one in eight American adults now taking GLP-1 medications like Ozempic and Wegovy, researchers at Georgia State University have uncovered why patients regain weight after stopping treatment — and a potential combination therapy that could solve the problem by targeting the brain's stress response system.